Nuvalent, Inc. Class A ((NUVL)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Nuvalent, Inc. is conducting a study titled ‘A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)’. The study aims to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose, and assess antitumor activity in patients with advanced or metastatic HER2-altered non-small cell lung cancer (NSCLC).
The intervention being tested is NVL-330, an oral drug designed to selectively inhibit tyrosine kinase, targeting HER2-altered NSCLC to potentially improve patient outcomes.
The study is interventional, with a non-randomized, sequential intervention model. It is open-label with no masking, and its primary purpose is treatment-focused.
The study began on July 22, 2024, with primary completion and estimated completion dates yet to be announced. The latest update was submitted on September 15, 2025, indicating ongoing recruitment.
This update could positively influence Nuvalent’s stock performance by showcasing progress in their drug pipeline, potentially attracting investor interest. The study’s focus on a niche cancer treatment could set Nuvalent apart from competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.